Sinovac Participates in Three Investor Conferences in September 2010
(Nasdaq: SVA), a leading
that Mr. Weidong YIN, Chairman, President & CEO, Mr. Jacob Chik Keung HO,
Acting CFO and Ms. Xiaohong WU, Senior Financial Manager, are scheduled to
participate in three upcoming investor conferences to be held in
2010
-- Morgan Stanley Global Healthcare Unplugged Conference, New York, NY,
September 13-14: Sinovac's presentation is scheduled for Tuesday,
September 14 at 2:10 pm ET.
-- Morgan Stanley China Global Healthcare Day, Boston, MA, September 15:
Sinovac is participating in one-on-meetings with investors that day.
-- UBS Global Life Sciences Conference, New York, NY, September 20-23:
Sinovac's presentation is scheduled for Monday, September 20 at
10:00 am ET.
A live webcast of the presentations at the Morgan Stanley Global
Healthcare Unplugged Conference and at the UBS Global Life Sciences Conference
will be available online on the Investor Relations Home page of the Sinovac’s
corporate Web site at http://www.sinovac.com .
About Sinovac
Sinovac Biotech Ltd. is a
focuses on the research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases. Sinovac’s
commercialized vaccine products include Healive(R) (hepatitis A), Bilive(R)
(combined hepatitis A and B), Anflu(R) (seasonal influenza), Panflu(TM)
(pandemic influenza (H5N1)), and Panflu.1(TM) (pandemic influenza A (H1N1)).
Sinovac is developing vaccines for enterovirus 71, universal pandemic
influenza, pneumococcal infection, Japanese encephalitis, and human rabies.
Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for
independently developed inactivated animal rabies vaccines. Its 30%-owned
joint venture, Sinovac Dalian, focuses on the research, development,
manufacturing and commercialization of vaccines, such as rabies, chickenpox,
mumps and rubella vaccines for human use.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements
are made under the “safe harbor” provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as “will,” “expects,” “anticipates,”
“future,” “intends,” “plans,” “believes,” “estimates” and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac’s beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any forward-
looking statement. Sinovac does not undertake any obligation to update any
forward-looking statement, except as required under applicable law.
For more information, please contact:
Chris Lee
Sinovac Biotech Ltd.
Tel: +86-10-8279-9659
Fax: +86-10-6296-6910
Email: lill@sinovac.com
Investors:
Stephanie Carrington/Amy Glynn
The Ruth Group
Tel: +1-646-536-7017/7023
Email: scarrington@theruthgroup.com
aglynn@theruthgroup.com
Media
Jason Rando
The Ruth Group
Tel: +1-646-536-7025
Email: jrando@theruthgroup.com
SOURCE Sinovac Biotech Ltd.